FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2187 May 18, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bonner, J. A. PubMed Citation

To the Editor: The trial of cetuximab plus radiotherapy for locally advanced head and neck cancer, as reported by Bonner et al. (Feb. 9 issue),¹ showed that patients with oropharyngeal squamous-cell carcinoma who received concomitant hyperfractionated radiotherapy obtained the greatest benefit from cetuximab. However, the study lacked adequate statistical power for subgroup analysis. Furthermore, the authors did not provide details regarding each radiotherapy regimen or primary sites in each group of patients in the trial.

Annie C. Ho, M.B., B.S., F.R.A.N.Z.C.R.
St. George Hospital
Kogarah, NSW 2217, Australia

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. [Free Full Text]

This article has been cited by other articles:

• Contractor, K. B., Aboagye, E. O. (2009). Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET. JNM 50: 97S-105S [Abstract] [Full Text]